Severe fluoropyrimidine toxicity in older adults with cancer with DPYD wild type.

ABSTRACT:

Background

Despite the implementation of DPYD genotype-guided dosing, approximately 1 in 3 patients receiving fluoropyrimidine-containing chemotherapy continues to experience severe toxicity. While clinical studies have demonstrated a favorable tolerance among highly selected fit older adults, real-world studies have shown an increased risk of toxicity.

Objective

To identify predictors of severe toxicity or treatment deintensification in older DPYD wild-type adults receiving fluoropyrimidine-containing chemotherapy.

Method

Patients wild type for four tested DPYD variants, aged ≥65 years, who participated in a prospective clinical trial investigating genotype-guided individualized fluoropyrimidine dosing, were eligible for the study. The association between tumor-, tre

SUBMITTER: Brokaar E 

PROVIDER: S-EPMC11837876 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature